Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control

NCT02352363 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT02352363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02352363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control
Lead sponsor
Acorda Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2015
Completion date
May 31, 2017
Enrollment
408 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease